Journal of Blood & Lymph

Hanaoka N

Publications

• Research Article
  An Optimal Approach for Fluoroquinolone Garenoxacin Prophylaxis in Patients with Hematological Malignancies and Chemotherapy-induced Neutropenia
  Author(s): Mushino T, Hanaoka N, Murata S, Kuriyama K, Hosoi H, Nishikawa A, Tamura S, Nakakuma H and Sonoki TMushino T, Hanaoka N, Murata S, Kuriyama K, Hosoi H, Nishikawa A, Tamura S, Nakakuma H and Sonoki T
  
  Antibiotic prophylaxis such as that with fluoroquinolone reportedly reduces infectious episodes in patients receiving chemotherapy regimens with the risk of febrile neutropenia. However, optimum patient characteristics, the timing of initiation, and antibiotics for prophylactic treatments have yet to be identified. We herein conducted a single-arm monocenter clinical study to elucidate the therapeutic profiles of fluoroquinolone garenoxacin prophylaxis for patients with hematological malignancies (HMs). Fever was not present for the duration of chemotherapyinduced neutropenia in 29 (43.9%) out of 66 patients. A shorter duration of prophylaxis until chemotherapy-induced neutropenia had a more potent effect on delaying febrile episodes, even in patients with fever. Excessive neutropenia (minimum zero neutrophils/l) negatively affected prophylactic effects. Garenoxacin accounted for 4.5%.. Read More»
  DOI: 10.4172/2165-7831.1000161

  Abstract PDF